Semaglutide 99% White powder High Quality semaglutide weight Pharmaceutical Grade

Purity：>99% , >98% (for tablets)

Indications:

1. An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .

2. To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease

Mechanism of Action:

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.

GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors.

   Semaglutide is a next-generation long-acting GLP-1 (Glucagon-Like Peptide-1) receptor agonist and a flagship peptide drug. Featuring high homology with human native GLP-1 in amino acid sequence, it achieves superior long-term efficacy, stability and bioactivity through structural modification, making it a core innovative peptide product in the field of metabolic disease treatment. Adopting a glucose-dependent working mechanism, Semaglutide precisely regulates human metabolic balance. It targets boosting insulin secretion and inhibiting glucagon release when blood glucose rises to stabilize glycemic control with an extremely low risk of hypoglycemia. Meanwhile, it delays gastric emptying and suppresses central appetite to reduce calorie intake for safe weight management, while delivering multiple clinical benefits including improved insulin resistance, cardiovascular protection and lipid metabolism regulation. Compared with conventional peptide drugs, Semaglutide possesses a longer half-life and lower administration frequency, enabling sustained and stable therapeutic effects and significantly improving medication convenience and patient compliance. Currently, Semaglutide is widely approved for blood glucose management in adult type 2 diabetes and weight control for obese and overweight populations, and also presents broad application prospects in cardiovascular risk intervention and metabolic syndrome regulation, emerging as a core R&D and industrialization hotspot in global innovative peptide drugs and metabolic health sectors. Leveraging its mature high-end peptide synthesis and purification technology system, the company supports customized R&D and large-scale production of high-purity, high-stability Semaglutide API and intermediates, with precise control over core indicators such as purity, impurity content and biological stability. It also provides professional process optimization, technology implementation and customized solution services, facilitating the domestic production and commercialization of high-end GLP-1 peptide drugs.